Compare AbCellera Biologics Inc (ABCL) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Lululemon Athletica Inc — how do they compare? AbCellera Biologics Inc trades at $7.12 (market cap $2.35B), while Lululemon Athletica Inc trades at $113.2 (market cap $13.13B). The key difference: Lululemon Athletica Inc is far larger — about 5.6× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Lululemon Athletica Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | LULU | |
|---|---|---|
Market Cap | $2.35B | $13.13B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $238.54 |
52-Week Low | $2.78 | $105.43 |
Enterprise Value | $1.99B | $13.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
LULU trades at $115.07, down 2.84% for the day, reflecting recent bearish sentiment amid a 45% year-to-date decline. The stock is near its pivot point of $115, with technical indicators signaling a bearish trend. Fundamentally, the company reported strong revenue of $10.59B in 2025 and a net income margin of 17.13%, with a low P/E of 9.36 suggesting undervaluation. Recent news highlights board settlement with founder Chip Wilson but also cultural missteps in China and a class-action lawsuit over tariff costs.
The outlook is mixed: attractive valuation and international growth potential contrast with North American weakness and brand reputation risks. Analyst consensus is a $130.53 price target with 41% buy ratings, but near-term volatility persists. Key risks include execution on guidance, competitive pressures, and macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
